GCBC Vaccines Pvt. Ltd.

GCBC Vaccines Pvt. Ltd. has emerged as a key player in India’s biotechnology landscape, continuing the legacy of Shantha Biotechnics, which pioneered the development and commercialization of recombinant human healthcare products in the country. Originally founded by Dr. Varaprasad Reddy in 1991, Shantha Biotechnics gained global recognition for its affordable vaccines like Shanvac-B® and Shanchol™, serving markets across Asia-Pacific, Africa, and Latin America. Today, GCBC Vaccines carries forward this mission, ensuring access to life-saving vaccines and expanding its reach through partnerships with global health organizations such as WHO, UNICEF, and PAHO.

Following its acquisition by Sanofi Pasteur in 2009, Shantha Biotechnics became Sanofi Healthcare India Pvt. Ltd. (SHIPL), significantly boosting the availability of high-quality, affordable vaccines in developing nations. In 2024, SHIPL transferred its vaccine manufacturing operations, including technology and licenses for key products, to GCBC Vaccines. Despite the transitional challenges, GCBC ensured continuity in vaccine supply, reaffirming its commitment to combating vaccine-preventable diseases.

Currently, GCBC Vaccines is focused on advancing research in infectious diseases and platform technologies. With two strategic business units—Vaccines & Biologics and Contract Manufacturing Organization (CMO)—the company is actively exploring collaborations to drive innovation and address critical healthcare needs globally. Its dedication to scientific excellence and global health impact positions GCBC at the forefront of the biotechnology sector.